GlassScriptPhysician profile
Donald B Sanders
NPI 1811995731
$23,090.38
in general payments reported to CMS, 2019-2025
55 companies · $2,803 in 2025
The $2,803 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,046 · 2020: $2,649 · 2021: $3,681 · 2022: $3,690 · 2023: $3,104 · 2024: $3,118 · 2025: $2,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,024.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,045.67 | 2019-2025 | Spravato, Xarelto |
| Amgen INC. | $2,023.91 | 2019-2025 | Repatha, Evenity, Repatha |
| Novo Nordisk INC | $2,009.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,860.14 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Abbvie INC. | $1,849.12 | 2021-2025 | Linzess, Ubrelvy, Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,636.68 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Pfizer INC. | $1,413.66 | 2019-2025 | |
| Lilly USA, LLC | $1,051.39 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $910.46 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $732.85 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $705.35 | 2019-2025 | Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $674.10 | 2022-2025 | Rexulti, Nuedexta |
| Sanofi-Aventis U.S. LLC | $547.28 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $479.23 | 2019-2025 | Zoryve, Livalo |
| Paratek Pharmaceuticals, INC. | $424.90 | 2022-2025 | Nuzyra |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.